drugset / Trial / NCT00912418
Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma
Parallel-groupOpen-labelTreatment
Summary
This study is an open-label, pilot study of an autologous tumor cell vaccine.
Timeline
- Start
- 2000-05-01
- Primary completion
- 2002-09-17
- Completion
- 2002-10-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | autologous tumor cells | Vaccine | — | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | — | — |
| Background | sargramostim | Protein / enzyme biologic | 225 ug | — |